Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer (MBC)
Phase of Trial: Phase I/II
Latest Information Update: 01 Jan 2015
At a glance
- Drugs Ixabepilone (Primary) ; Sorafenib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 07 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 10 Sep 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 09 Jul 2013 Planned end date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.